Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership

Miami's emergence as a premium market and destination for consumer skincare, consumer health, and aesthetic treatments aligns closely with Galderma's ambitions for its U.S. business, which is the company's largest region globally and a key driver of future growth.

"Miami's creativity, energy and forward-thinking spirit are consistent with Galderma's ambitions. The city's emergence as a premium destination and a trend-setter in areas closely aligned to our activities, as well as its fast-growing healthcare professional community, makes Miami a natural choice for our U.S. headquarters. Being in Miami will enrich our business with top talent that will prove invaluable to our future success."

FLEMMING ØRNSKOV, M.D., MPH 
 CHIEF EXECUTIVE OFFICER
GALDERMA

The Miami metro area boasts one of the highest concentrations of medical spas and dermatological aesthetic clinics in the United States, with aesthetic procedures growing at an estimated 30% year-over-year. It also hosts the nation's second-largest medical district, the Miami Health District, with numerous hospitals and research facilities. With over 186,000 healthcare-related jobs and significant growth in startups, Florida is a hub for innovation in health and advanced medical technologies. Miami plays an important role in this ecosystem, with renowned research institutions and medical centers that house dedicated clinical teams focused on dermatology.

"We are delighted to welcome Galderma to the Miami-Dade County area, which has witnessed considerable growth recently as companies increasingly find it to be an attractive location for investment. Miami-Dade has established itself as a key player in the life sciences and healthcare industry and having the pure-play dermatology industry leader anchor its U.S. business here will only bolster the region's reputation for innovation in this sector."

RODRICK MILLER
PRESIDENT AND CHIEF EXECUTIVE OFFICER
MIAMI-DADE BEACON COUNCIL

In addition to its new headquarters in Miami, Galderma will maintain a strong presence across several U.S. locations. Boston, MA, will remain the hub for the company's U.S. Therapeutic Dermatology business and U.S. Research and Development organization. Carlsbad, CA, will continue as a hub for Alastin^®, the company's premium, physician-dispensed skincare brand. The Dallas, TX, office will continue as one of Galderma's key U.S. sites while the company's North America distribution center will remain in Fort Worth, TX.

APPOINTING A NEW LEADER FOR GALDERMA U.S.
Galderma has also announced today the appointment of Heather Wallace as President of Galderma U.S. Heather will be based in Miami. A proven senior business leader with deep expertise in dermatology and consumer health, she brings a strong track record of delivering commercial success and operational excellence.

Heather previously led high-performing teams as Chief Executive Officer of Curology, the leader in personalized prescription skincare, and as President of the Americas region for Revlon, where she oversaw strategic and cultural transformation efforts to maximize profitability in the company's largest region. Her appointment signals Galderma's commitment to strengthening its U.S. leadership with forward-thinking talent capable of driving sustained growth in a dynamic and highly competitive landscape.

GALDERMA'S LEADING PORTFOLIO OF PREMIUM BRANDS
Galderma's synergistic portfolio of flagship brands holds leading market positions in Dermatological Skincare, Injectable Aesthetics, and Therapeutic Dermatology.

In Dermatological Skincare, Galderma is best known for Cetaphil^®, a leading dermatologist recommended brand for sensitive skin with more than 70-year heritage in the United States. Galderma's premium portfolio also includes the physician-dispensed skincare brand Alastin^®, a leader in medical-grade peptide-based regenerative skincare.

In Injectable Aesthetics, Galderma has a long history of aesthetics innovation and deep expertise in neuromodulators, as well as hyaluronic acid (HA) fillers and biostimulators.

In Therapeutic Dermatology, Galderma brands hold leading positions in acne and rosacea and the company recently launched the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31 in prurigo nodularis and atopic dermatitis.

ABOUT GALDERMA
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

For further information:

SOURCE Galderma